- Home
- ERAS vs DH Comparison
ERAS vs DH Comparison
Compare ERAS & DH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- DH
- Stock Information
- Founded
- ERAS 2018
- DH 2011
- Country
- ERAS United States
- DH United States
- Employees
- ERAS N/A
- DH N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- DH Computer Software: Prepackaged Software
- Sector
- ERAS Health Care
- DH Technology
- Exchange
- ERAS Nasdaq
- DH Nasdaq
- Market Cap
- ERAS 484.4M
- DH 429.4M
- IPO Year
- ERAS 2021
- DH 2021
- Fundamental
- Price
- ERAS $1.41
- DH $3.86
- Analyst Decision
- ERAS Strong Buy
- DH Hold
- Analyst Count
- ERAS 6
- DH 10
- Target Price
- ERAS $4.83
- DH $5.10
- AVG Volume (30 Days)
- ERAS 852.4K
- DH 393.0K
- Earning Date
- ERAS 08-11-2025
- DH 08-07-2025
- Dividend Yield
- ERAS N/A
- DH N/A
- EPS Growth
- ERAS N/A
- DH N/A
- EPS
- ERAS N/A
- DH N/A
- Revenue
- ERAS N/A
- DH $247,913,000.00
- Revenue This Year
- ERAS N/A
- DH N/A
- Revenue Next Year
- ERAS N/A
- DH $1.69
- P/E Ratio
- ERAS N/A
- DH N/A
- Revenue Growth
- ERAS N/A
- DH N/A
- 52 Week Low
- ERAS $1.01
- DH $2.15
- 52 Week High
- ERAS $3.31
- DH $5.68
- Technical
- Relative Strength Index (RSI)
- ERAS 40.59
- DH 44.53
- Support Level
- ERAS $1.34
- DH $3.98
- Resistance Level
- ERAS $1.81
- DH $4.25
- Average True Range (ATR)
- ERAS 0.12
- DH 0.17
- MACD
- ERAS -0.03
- DH -0.05
- Stochastic Oscillator
- ERAS 7.45
- DH 12.99
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About DH Definitive Healthcare Corp.
Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.